Cargando…

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation

OBJECTIVE: Systemic inflammation predisposes acutely decompensated (AD) cirrhosis to the development of acute-on-chronic liver failure (ACLF). Supportive treatment can improve AD patients, becoming recompensated. Little is known about the outcome of patients recompensated after AD. We hypothesise th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monteiro, Sofia, Grandt, Josephine, Uschner, Frank Erhard, Kimer, Nina, Madsen, Jan Lysgård, Schierwagen, Robert, Klein, Sabine, Welsch, Christoph, Schäfer, Liliana, Jansen, Christian, Claria, Joan, Alcaraz-Quiles, José, Arroyo, Vicente, Moreau, Richard, Fernandez, Javier, Bendtsen, Flemming, Mehta, Gautam, Gluud, Lise Lotte, Møller, Søren, Praktiknjo, Michael, Trebicka, Jonel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815638/ https://www.ncbi.nlm.nih.gov/pubmed/32241903 http://dx.doi.org/10.1136/gutjnl-2019-320170

Ejemplares similares

Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2021)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS
por: Queck, Alexander, et al.
Publicado: (2020)

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis
por: Alvarez-Silva, Camila, et al.
Publicado: (2019)

Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials
por: Kimer, Nina, et al.
Publicado: (2012)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
por: Kimer, Nina, et al.
Publicado: (2020)

Albumin in decompensated cirrhosis: new concepts and perspectives
por: Bernardi, Mauro, et al.
Publicado: (2020)

Effect of COVID-19 on presentations of decompensated liver disease in Scotland
por: Manship, Thomas, et al.
Publicado: (2022)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis
por: Queck, Alexander, et al.
Publicado: (2019)

Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease
por: Trebicka, Jonel, et al.
Publicado: (2022)

Epidemiology of liver transplantation and post-LT complications in Germany: nationwide study (2005–2018)
por: Gu, Wenyi, et al.
Publicado: (2023)

Hepatic decompensation in the absence of obvious precipitants: the potential role of cytomegalovirus infection/reactivation
por: Rosi, Silvia, et al.
Publicado: (2015)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation
por: Gananandan, Kohilan, et al.
Publicado: (2023)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review
por: O’Connell, Malene Barfod, et al.
Publicado: (2023)

Predicting 1-year mortality among patients with decompensated cirrhosis: results of a multicentre evaluation of the Bristol Prognostic Score
por: Bowers, Sarah Pauline, et al.
Publicado: (2022)

Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis
por: Khamri, Wafa, et al.
Publicado: (2022)

Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension
por: Klein, Sabine, et al.
Publicado: (2016)

β-Arrestin2 is increased in liver fibrosis in humans and rodents
por: Schierwagen, Robert, et al.
Publicado: (2020)

Characteristics of randomised trials on diseases in the digestive system registered in ClinicalTrials.gov: a retrospective analysis
por: Wildt, Signe, et al.
Publicado: (2011)

Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
por: Kronborg, Thit M., et al.
Publicado: (2023)

Left Ventricular Longitudinal Contractility Predicts Acute‐on‐Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt
por: Jansen, Christian, et al.
Publicado: (2019)

The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease
por: Schierwagen, Robert, et al.
Publicado: (2020)

Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation
por: Casey, Stephen, et al.
Publicado: (2019)

PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF
por: Li, Jiang, et al.
Publicado: (2022)

A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
por: Xie, Yanan, et al.
Publicado: (2022)

Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation
por: Stoffers, Philipp, et al.
Publicado: (2022)

Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis
por: Mohr, Raphael, et al.
Publicado: (2018)

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case–control study
por: Xu, Xiaomei, et al.
Publicado: (2021)

Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy—the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study
por: Zhao, Mirabella, et al.
Publicado: (2020)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis
por: Schierwagen, Robert, et al.
Publicado: (2020)

Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough
por: Laleman, Wim, et al.
Publicado: (2018)

Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats
por: Klein, Sabine, et al.
Publicado: (2019)

Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt
por: Praktiknjo, Michael, et al.
Publicado: (2019)

Role of circulating angiogenin levels in portal hypertension and TIPS
por: Queck, Alexander, et al.
Publicado: (2021)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v5nv2tuvutgaevc9j4rtoromcu